1. Acute Myeloid Leukemia Presenting Less Than 3 Weeks After Living Donor Kidney Transplant: A Case Report.
- Author
-
Yu J, Sherburne B, Chen YB, Kutzler HL, Tremaglio J, Rochon C, Sheiner P, and Serrano OK
- Subjects
- Bone Marrow pathology, Cell Cycle Proteins genetics, Chimerism, Chromosomal Proteins, Non-Histone genetics, DNA-Binding Proteins genetics, Dioxygenases, Graft vs Host Disease etiology, Haplotypes, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Myeloid, Acute etiology, Leukemia, Myeloid, Acute genetics, Leukemia, Myeloid, Acute therapy, Living Donors, Male, Middle Aged, Mutation, Proto-Oncogene Proteins genetics, Remission Induction, Kidney Transplantation adverse effects, Leukemia, Myeloid, Acute diagnosis
- Abstract
Acute myeloid leukemia (AML) is a rare malignancy with increased incidence in the kidney transplantation (KT) population for which immunosuppression has been implicated as a putative cause. The average time interval from KT to AML development is 5 years. We present the case of a 61-year-old man who was found to have peripheral blood blasts on a postoperative day 20 routine blood draw after an uneventful unrelated living donor kidney transplant. He subsequently had a bone marrow biopsy and next-generation sequencing (NGS)-based molecular testing, which demonstrated AML characterized by SMC1A and TET2 mutations. He received induction chemotherapy followed by hematopoietic cell transplantation (HCT) from the kidney donor, who happened to be matched at one haplotype. At 12 months after his HCT and 15 months after his KT, his AML remained in remission, normal renal function was preserved, no active graft-versus-host disease was present, and immunosuppression was tapering. With full donor-derived hematopoietic chimerism, we expect to be able to discontinue immunosuppression shortly, thereby achieving tolerance. The short time interval between KT and development of AML suggests the malignancy was likely present before KT. Modern NGS-based analysis offers a promising method of identifying transplant candidates with unexplained hematologic abnormalities on pre-KT testing who may benefit from formal hematologic evaluation., (Copyright © 2021 Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF